Beta Bionics Receives FDA Breakthrough Device Designation for the iLet Bionic Pancreas System

Boston, MA -July 1, 2019 - Beta Bionics, Inc. — a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world`s first fully automated bionic pancreas — today announced that the company has completed a S63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the total combined Series B and B2 financings to just over $126 million. Beta Bionics, Inc. announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its investigational iLet Bionic Pancreas System.